Stabilized human papillomavirus formulations
US6358744B1 · kind B1 · utility
5Cited by
1References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 24, 2000 |
| Grant date | Mar 19, 2002 |
| Priority date | — |
| Expiry date | Jul 24, 2020 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10T436/108331
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Human papillomavirus (HPV) antigen formulations are disclosed which prevent protein aggregation and show prolonged stability as aqueous solutions. These formulations comprise a salt (such as sodium chloride) and a non-ionic surfactant (Polysorbate 80 such as Tween 80®) in physiologically acceptable concentrations.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.